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was to collect, in routine clinical practice, data about consequences of switching
from intravenous (IV) EPO to IV DA in patients (pts) with chronic kidney disease
(CKD) receiving dialysis ( 12 months). METHODS: This French monocentre obser-
vational study included adults with CKD receiving dialysis switched from EPO to
DA in July 2010. Data related to EPO and DA dosing and dose frequency, Hb levels,
and iron statuses were collected retrospectively over 36 weeks before the conver-
sion and 36 weeks after the conversion. The primary endpoint estimated the dose
conversion ratio (DCR) between mean EPO doses (UI) and DA (g) during 4 weeks
pre-conversion and 21-24 weeks post-conversion. The mean DCR was determined
with a regression-based method using ordinary least squares (LSQ). RESULTS: A
total of 93 pts were enrolled in this study, (61.3 % female, mean age 70.3 years
(mean time on dialysis 5.2 years). The primary etiologies of CKD were mainly dia-
betes (37.6 %) and hypertension (12.9 %). The arithmetic mean ( SD) EPO dose/
injection at inclusion was 4193  3417 UI with the following injection frequency:
x3/week (44.1 %), x2/week (32.3 %), x1/week (21.5 %) or other (2.1 %). The mean (
SD) DCR on the evaluable population (83 patients, 10 excluded due to missing data)
was 271.3  30.4 (95% CI 264.7, 277.9). The mean ( SD) Hb values were equivalent
over the pre- and post-conversion periods 11.2  0.9 and 11.1  1.0 g/dL, respec-
tively. Iron status was also similar. CONCLUSIONS: In routine clinical practice, the
mean DCR observed in our French dialysis centre, was higher than the factor 200UI:
1g recommended in the DA Summary of Product Characteristics and applied at
switch.
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OBJECTIVES: Kidney transplantation is perceived to be highly cost effective; the
cost of post-transplant management is modest compared to dialysis and quality of
life is significantly improved. While graft survival rates have improved substan-
tially in recent years, on average, graft failure rates are currently 2.9% per annum
across the UK. The objective of this study was to quantify the minimum graft
survival time required for transplantation to remain cost saving compared to
dialysis. METHODS: We utilized a simple decision analytic model with published
input costs for dialysis; immunosuppression and other post-transplant manage-
ment costs were obtained from the PORTRAIT Study (a retrospective observational
study of renal transplant patients) and UK NHS reference costs used for transplan-
tation. We compared the costs of continued dialysis with transplantation and eval-
uated the number of years of functioning graft required for transplantation to
remain cost saving. Future costs were discounted at 3.5%. RESULTS: Over a 10 year
time horizon the total per-patient costs associated with remaining on dialysis was
£394,379; over the same period the total per-patient cost for a functioning graft
were £118,049 representing a saving to the NHS of £276,330 per-patient. Patients
with a 3-year functioning graft prior to returning to dialysis cost an additional
£5,723 compared to remaining on dialysis while 4-year graft survival was cost
saving. CONCLUSIONS: For kidney transplantation to be cost saving recipients
must maintain at least 3 years of functioning graft. In the UK between 3% to 13% of
adult kidney transplants from deceased donors and 2% to 8% from living donors fail
within one year necessitating a return to dialysis. Consequently, a substantial
number of transplant recipients in the UK incur additional and substantial expen-
diture due to poor graft survival rates and, therefore, management strategies to
maximize graft survival should be prioritized in these patients.
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Chronic Kidney Disease (CKD) is the second most frequent complication in 7 mil-
lion diabetes patients in Germany. However, available data on burden of disease is
intransparent. OBJECTIVES: To obtain a comprehensive picture on the conse-
quences of CKD in diabetes patients in Germany from the epidemiological, clinical
and health economics perspective based on available scientific literature.
METHODS: A semi-structured systematic literature review in MEDLINE, CO-
CHRANE, EMBASE and national associations over the last 10 years (2001-2011) and
relevant congress abstracts over the last 2 years. Fields of interest (reviewed sepa-
rately) were epidemiology, health economics, burden of disease and treatment
guidelines with reference to CKD and diabetes. As a conclusion, we conducted a
data gap analysis. RESULTS: Twenty-one epidemiological, 12 burden of disease, 9
health economic full-text articles and 5 treatment guidelines were identified. Prev-
alence of CKD in diabetes patients was 39% but only 0.5% reached dialysis. Acces-
sion rates within all CKD stages were missing. Yearly mortality rates within diabe-
tes patients in dialysis were around 20%. An albumin guideline adherence (albumin
level below 40g/L) could save 23,578 life years. SF-36 was most common generic
HRQoL and KDQoL as disease specific. No data on QoL in pre-dialysis was available.
Highest impairment was physical and emotional functioning. Poor sleep quality
(63%) was significantly associated with higher risk of death (RR1.16, p0.002).
Health care costs were significantly associated with progression of CKD stages.
Direct costs of dialysis were 54,777 €. 60% of dialysis patients lived below the pov-
erty level. CONCLUSIONS: Higher evidence on epidemiological data and disease pro-
gression is desirable. Data within patients in CKD 1-4 was limited or not available. Produc-
tivity lossmighthaveasignificant impactontheburdenofdiseasebutnodatawasfound.
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OBJECTIVES: The number of patients suffering from chronic kidney disease (CKD)
is about 10% of the total world population and 50% of patients with hypertension
and diabetes. About 3400 patients with CKD in Ukraine are treated by hemodialysis.
All these patients need treatment of anemia that associates with CKD by erythro-
poietins (EPs). In Ukraine as well as alfa- and beta-erythropoietins a fundamentally
new product – continuous erythropoietin receptor activator (CERA) are recom-
mended. Its main feature - administration twice a month in treated dose and once
a month in maintenance dose, while others EPs are administrated 2-3 times a
week. The purpose of research is comparative pharmacoeconomic evaluation of
maintenance treatment of anemia in patients with CKD on hemodialysis stage by
different drugs of erythropoietin. METHODS: Decision tree and cost-effectiveness
analysis were used. The costs for EP drugs were determined according to the price
list Pharmacy (2011). The data about equivalent doses of different EPs and their
effectiveness are taken from the results of randomized clinical trials phase III
MAXIMA, PROTOS and RUBRA. RESULTS: Showed that prolonged use of CERA,
which is administrated once a month, effectively maintained stable hemoglobin
level previously is achieved by the administration of shorter-acting EPs (3 times a
week). With appropriate regimen of administration in equivalent doses (according
to the instruction of CERA) the average costs of CERA treatment per patient on
hemodialysis are $173/week (i/v route of administration) and $130/week (s/c route
of administration). The average costs for using the shorter-acting EP drugs are
$267-194/week and $133-182/week respectively. CONCLUSIONS: The use of CERA
in patients with CKD on hemodialysis at the compensative stage instead of shorter-
acting EPs saves about 5-35% of cost for anemia pharmacotherapy. The effective-
ness and safety of therapy do not change.
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OBJECTIVES: Previous research has described treatment failure as discontinuation
of the first anticholinergic or switching in persons with continuous anticholinergic
use. Such research does not account for persons who may restart anticholinergic
use following a period of discontinuation. The objective of this study was to eval-
uate the dynamics of treatment failure in patients with OAB following discontin-
uation of the first anticholinergic.METHODS: Patients in a US commercial database
between January 2005 and June 2010 with  1 filled prescription for an anticholin-
ergic for OAB were included. Treatment failure was defined as patients who dis-
continued therapy (treatment gap of45 days) or switched medications. RESULTS:
There were 182,586 patients who met all inclusion criteria. Treatment failure was
present in a total of 83.4% patients, with 78.3% of patients discontinuing first antich-
olinergic therapy and 5.1% of continued users switching. A total of 30.4% of persons
who discontinued treatment rechallenged after the 45 day treatment gap, with 66.7%
resuming treatment with their original agent. Overall, 54.5% of patients discontinued
anticholinergic treatment permanently within the one year study period. A total of
14.1% of patients switched at least once throughout the study, and patients received
an average of 1.2 (SD: 0.4) unique anticholinergic agents. Of those who initially
switched to a second anticholinergic, 69.6% of patients failed treatment for a second
time either by discontinuing treatment (48.8%) or switching to a third agent (20.8%). A
separate analysis requiring  2 fills found that 85% of patients who switched also
discontinued within the one year study frame. Persons on sustained release anticho-
linergics were less likely to experience treatment failure than those on immediate
release anticholinergics (odds ratio: 0.78 [0.76-0.80], P0.0001).CONCLUSIONS: Treat-
ment failure was high in patients taking anticholinergics for OAB even after taking
restarts into account. Most patients who switched from their first anticholinergic ther-
apy experienced a second treatment failure.
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OBJECTIVES: Kaplan-Meier (KM) curves are commonly used to report time-to-
event outcomes like overall survival (OS) and progression-free survival. For studies
not explicitly reporting hazard ratio (HR) and confidence intervals (CI), KM curves
can be utilised to estimate these summary statistics for conducting a meta-analy-
sis. Here, we validate the method proposed by Parmar and colleagues for estimat-
ing HR (95%CI) by reading the KM curves. METHODS: Ten randomised controlled
trials reporting HR (95%CI) and the associated KM curve for OS were randomly
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